Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.40 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8797056 | 1.00 | MME (0.42) | MMECACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL28086823 | 0.86 | KMT2A (0.39) | ADRA1ATDP1CA1CA2CA7 | |
| SCHEMBL8129976 | 0.86 | CYP2D6 (0.33) | MMECACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL764175 | 0.82 | FOLH1 (0.39) | CTSLCTSBCTSSCTSK | |
| SCHEMBL16350134 | 0.82 | FOLH1 (0.39) | CTSLCTSBCTSSCTSK | |
| SCHEMBL3996454 | 0.82 | CTSK (0.34) | ADRA1ACTSSCTSKSLC1A3SLC1A2 | |
| SCHEMBL3996456 | 0.82 | CTSK (0.34) | ADRA1ACTSSCTSKSLC1A3SLC1A2 | |
| SCHEMBL21996181 | 0.81 | CA2 (0.37) | CTSSCTSKCA1CA2MEN1 | |
| SCHEMBL6250770 | 0.79 | CYP2D6 (0.39) | CA2AAK1MEN1KMT2AGAA | |
| SCHEMBL8133983 | 0.79 | CYP2D6 (0.39) | CA2AAK1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080279769-A1 | Enzyme Inhibitor Imaging Agents | SOLBAKKEN MAGNE | 2008-11-13 | — | — | US | disclosed |
| EP-1796736-A2 | METALLOPROTEINASE INHIBITOR IMAGING AGENTS | GE Healthcare Limited (GB) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006032911-A2 | METALLOPROTEINASE INHIBITOR IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2006-03-30 | — | — | WO | disclosed |
| EP-0777646-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2001-09-05 | — | — | EP | disclosed |
| EP-0874799-B1 | PREPARATION OF ALLYL SUCCINATE DERIVATIVES AND STARTING MATERIALS THEREFOR | BRITISH BIOTECH PHARM (GB) | 2000-05-31 | — | — | EP | disclosed |
| US-5952320-A | USEFUL IN THE TREATMENT OF DISEASES IN WHICH MATRIX METALLOPROTEINASE PLAY A ROLE; MATRIX METALLOPROTEINASE INHIBITING COMPOSITIONS | ABBOTT LABORATORIES (US) | 1999-09-14 | — | — | US | disclosed |
| US-5936116-A | Preparation of allyl succinate derivatives and starting materials therefor | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-10 | — | — | US | disclosed |
| US-5763621-A | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-06-09 | — | — | US | disclosed |
| EP-0807114-A1 | BRIDGED INDOLES AS MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996006074-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-02-29 | — | — | WO | disclosed |
| EP-0445206-B1 | HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS | BRITISH BIO TECHNOLOGY (GB) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279769-A1 | Enzyme Inhibitor Imaging Agents | MMP3, MMP1, MMP10 | MME 36/4885CACNA2D1 3799/4885CACNB3 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.